ライフサイエンスコーパス: acute chest syndrome

1 ckle cell disease-related events, especially acute chest syndrome.

2 ies, or with severe or recurrent episodes of acute chest syndrome.

3 ssemia was admitted to the internal ward for acute chest syndrome.

4 equency of acute pain episodes or history of acute chest syndrome.

5 death, stroke, frequent pain, and recurrent acute chest syndrome.

6 ad frequent pain, and 3 (1.8%) had recurrent acute chest syndrome.

7 is area are current and uniquely relevant to acute chest syndrome.

8 rienced further episodes of pain, stroke, or acute chest syndrome.

9 hospitalized with mild to moderately severe acute chest syndrome.

10 ive crisis, a composite of painful crisis or acute chest syndrome.

11 requent pain (17 [24 percent]), or recurrent acute chest syndrome (10 [14 percent]).

12 %), acute splenic sequestration (19.1%), and acute chest syndrome (11.8%).

13 patients) included ileus (5), bleeding (4), acute chest syndrome (5), pneumonia (2), portal vein thr

14 evels are associated with increased rates of acute chest syndrome (ACS) and pain.

15 ive Study of Sickle Cell Disease (CSSCD) for acute chest syndrome (ACS) and painful crisis.

16 Pain and acute chest syndrome (ACS) episodes are 2 of the most co

17 Patients experienced 7.5 acute chest syndrome (ACS) events per 100 person-years,

18 Patients experienced 7.5 acute chest syndrome (ACS) events/100 person-years, comp

19 Acute chest syndrome (ACS) in patients with sickle cell

20 Acute chest syndrome (ACS) is a common, serious complica

21 Acute chest syndrome (ACS) is a leading cause of death i

22 The prevention and treatment of acute chest syndrome (ACS) is a major clinical concern i

23 Acute chest syndrome (ACS) is an important cause of morb

24 Acute chest syndrome (ACS) is associated with significan

25 Acute chest syndrome (ACS) is the leading cause of death

26 Acute chest syndrome (ACS) is the presence of a new pulm

27 Patients with severe acute chest syndrome (ACS) requiring endotracheal intuba

28 Acute chest syndrome (ACS) was the most common (35%) cau

29 e contributing factor for the development of Acute Chest Syndrome (ACS), a major cause of morbidity a

30 ications, including vaso-occlusive episodes, acute chest syndrome (ACS), pain, and stroke.

31 vasoactive mediator endothelin (ET-1) in the acute chest syndrome (ACS), we incubated bovine pulmonar

32 her than dactylitis, (2) dactylitis, and (3) acute chest syndrome (ACS).

33 e abnormal in children with a history of the acute chest syndrome (ACS).

34 Those with H1N1 influenza more often had acute chest syndrome (ACS; 34% vs 13%, P = .01) and requ

35 tted with sickle cell crisis, complicated by acute chest syndrome, acute respiratory distress syndrom

36 e substantially reduces episodes of pain and acute chest syndrome, admissions to hospital, and transf

37 left lung following exchange transfusion for acute chest syndrome and hyper-hemolytic syndrome.

38 generation of F2 isoprostanes, occurs during acute chest syndrome and may have an important role in t

39 stress may contribute to the pathogenesis of acute chest syndrome and measured F2 isoprostanes, a non

40 usion for prevention of stroke, treatment of acute chest syndrome and perioperative transfusion manag

41 ions of SCD are of particular importance, as acute chest syndrome and pulmonary hypertension have the

42 sickle cell disease, as well as a link with acute chest syndrome and vaso-occlusive crisis.

43 Mortality, HbF levels, painful episodes, acute chest syndrome, and blood cell counts.

44 ses significantly, decrease the incidence of acute chest syndrome, and decrease the need for blood tr

45 centration and rate of and recent episode of acute chest syndrome, and elevated systolic blood pressu

46 velocity, white blood cell count, history of acute chest syndrome, and hemoglobin levels, demonstrate

47 and recurrent episodes of pain, dactylitis, acute chest syndrome, and hospitalization; even infants

48 splenic sequestration, or priapism) and the acute chest syndrome, and patient-reported outcomes were

49 ion associated with increased rates of pain, acute chest syndrome, and premature death in human sickl

50 bF, lowers rates of pain crisis, episodes of acute chest syndrome, and requirements for blood transfu

51 cute exacerbation of asthma or an episode of acute chest syndrome are two distinct entities that need

52 increase in F2 isoprostanes in patients with acute chest syndrome as compared with normal volunteers.

53 t pulmonary manifestations of SCD, including acute chest syndrome, asthma, and pulmonary hypertension

54 cell disease include airway hyperreactivity, acute chest syndrome, chronic sickle lung disease, pulmo

55 Acute chest syndrome describes new respiratory symptoms

56 Individuals who had acute chest syndrome during the trial had 32% mortality

57 Risk factors for asthma exacerbation and an acute chest syndrome episode are similar, and both can p

58 usive pain crises per year (n = 12), or >/=2 acute chest syndrome episodes (n = 4) in the 2 years pre

59 , children with sickle cell disease who have acute chest syndrome episodes have worse pulmonary funct

60 sed incidence of vaso-occlusive pain events, acute chest syndrome episodes, and earlier death.

61 function than those who have not experienced acute chest syndrome episodes.

62 cy and severity of vaso-occlusive crises and acute chest syndrome episodes.

63 of eight patients transplanted for recurrent acute chest syndrome had stable pulmonary function.

64 ted crises (defined as crises other than the acute chest syndrome, hepatic sequestration, splenic seq

65 p<0.0001), with some evidence for decreased acute chest syndrome, hospitalisation rates, and transfu

66 t period, but significant benefits for pain, acute chest syndrome, hospitalizations, and transfusions

67 enter study, we analyzed 671 episodes of the acute chest syndrome in 538 patients with sickle cell di

68 roved pulmonary hypertension associated with acute chest syndrome in sickle cell disease, and several

69 have been implicated in the pathogenesis of acute chest syndrome in subjects with sickle cell anemia

70 ammatory state" that predisposes patients to acute chest syndrome in the setting of triggering factor

71 02; 95% CI 1.00-1.003; P = .015), and higher acute chest syndrome incidence rate (HR per event/year 1

72 Acute chest syndrome is a frequent cause of acute lung d

73 Among patients with sickle cell disease, the acute chest syndrome is commonly precipitated by fat emb

74 The acute chest syndrome is the leading cause of death among

75 Among patients with a history of acute chest syndrome, lung function stabilized; among pa

76 ious complications and organ damage, such as acute chest syndrome, multiorgan failure, and sudden dea

77 uded a history of stroke (n = 12), recurrent acute chest syndrome (n = 5), and recurrent painful cris

78 10 (91%) of 11 serious adverse events were acute chest syndrome (nine in the no-preoperative-transf

79 atients during vaso-occlusive crisis and the acute chest syndrome, nitric oxide is destroyed by incre

80 The pulmonary findings of acute chest syndrome of sickle cell disease have been we

81 itric oxide metabolism is altered during the acute chest syndrome of sickle cell disease.

82 of hypoperfusion/hypoxia, as observed during acute chest syndromes or acute anemic events (AAE), and

83 ity compared with 18% of individuals without acute chest syndrome (P =.02).

84 een patients with sickle cell disease during acute chest syndrome (pre- and postexchange transfusion)

85 Acute chest syndrome-related and all-cause 7- and 30-day

86 (vaso-occlusive painful crisis, dactylitis, acute chest syndrome, splenic sequestration, or blood tr

87 Symptoms include chronic anemia, acute chest syndrome, stroke, splenic and renal dysfunct

88 When the acute chest syndrome was diagnosed, patients had hypoxia

89 A specific cause of the acute chest syndrome was identified in 38 percent of all